Citigroup’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-14
| Closed | -$46 | – | 6097 |
|
|
2022
Q4 | $46 | Hold |
14
| – | – | ﹤0.01% | 5671 |
|
|
2022
Q3 | $0 | Sell |
14
-459
| -97% | -$1.57K | ﹤0.01% | 6694 |
|
|
2022
Q2 | $1K | Sell |
473
-822
| -63% | -$3.81K | ﹤0.01% | 6175 |
|
|
2022
Q1 | $10K | Buy |
+1,295
| New | +$13.2K | ﹤0.01% | 5566 |
|
|
2021
Q4 | – | Sell |
-193
| Closed | -$4.85K | – | 6209 |
|
|
2021
Q3 | $8K | Sell |
193
-99
| -34% | -$4.27K | ﹤0.01% | 5536 |
|
|
2021
Q2 | $12K | Sell |
292
-21
| -7% | -$923 | ﹤0.01% | 5598 |
|
|
2021
Q1 | $15K | Sell |
313
-535
| -63% | -$31.1K | ﹤0.01% | 5420 |
|
|
2020
Q4 | $84K | Buy |
848
+655
| +339% | +$57.4K | ﹤0.01% | 5675 |
|
|
2020
Q3 | $14K | Sell |
193
-684
| -78% | -$59.7K | ﹤0.01% | 6432 |
|
|
2020
Q2 | $93K | Buy |
877
+134
| +18% | +$15.9K | ﹤0.01% | 5633 |
|
|
2020
Q1 | $66K | Buy |
743
+262
| +54% | +$31.2K | ﹤0.01% | 5717 |
|
|
2019
Q4 | $55K | Sell |
481
-441
| -48% | -$33.2K | ﹤0.01% | 6230 |
|
|
2019
Q3 | $57K | Sell |
922
-211
| -19% | -$16.9K | ﹤0.01% | 6047 |
|
|
2019
Q2 | $88K | Sell |
1,133
-33
| -3% | -$3.75K | ﹤0.01% | 5992 |
|
|
2019
Q1 | $157K | Sell |
1,166
-5
| -0.4% | -$525 | ﹤0.01% | 5327 |
|
|
2018
Q4 | $94K | Buy |
1,171
+38
| +3% | +$3.75K | ﹤0.01% | 5706 |
|
|
2018
Q3 | $119K | Buy |
1,133
+379
| +50% | +$36.1K | ﹤0.01% | 5732 |
|
|
2018
Q2 | $75K | Sell |
754
-433
| -36% | -$49.1K | ﹤0.01% | 5965 |
|
|
2018
Q1 | $150K | Buy |
1,187
+521
| +78% | +$81.2K | ﹤0.01% | 5254 |
|
|
2017
Q4 | $111K | Sell |
666
-2,231
| -77% | -$571K | ﹤0.01% | 5552 |
|
|
2017
Q3 | $912K | Buy |
2,897
+777
| +37% | +$245K | ﹤0.01% | 3479 |
|
|
2017
Q2 | $630K | Buy |
2,120
+2,085
| +5,957% | +$558K | ﹤0.01% | 3775 |
|
|
2017
Q1 | $8K | Buy |
+35
| New | +$6.05K | ﹤0.01% | 6653 |
|
|
2016
Q2 | – | Sell |
-395
| Closed | -$45K | – | 7575 |
|
|
2016
Q1 | $45K | Buy |
395
+379
| +2,369% | +$42.9K | ﹤0.01% | 6169 |
|
|
2015
Q4 | $2K | Buy |
16
+10
| +167% | +$1.5K | ﹤0.01% | 7302 |
|
|
2015
Q3 | $1K | Sell |
6
-1
| -14% | -$130 | ﹤0.01% | 7252 |
|
|
2015
Q2 | $1K | Sell |
7
-641
| -99% | -$149K | ﹤0.01% | 7376 |
|
|
2015
Q1 | $212K | Buy |
648
+574
| +776% | +$204K | ﹤0.01% | 4480 |
|
|
2014
Q4 | $30K | Buy |
+74
| New | +$19.3K | ﹤0.01% | 6010 |
|
Other funds holding CALA
Citigroup's CALA Position: Q1 2023 in Review
Citigroup sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 14 shares — an estimated $46 sold.
Citigroup first reported a position in CALA in Q4 2014 and held it in 29 quarters. The position peaked at $912K in Q3 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- Citigroup reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- Citigroup sold 14 Calithera Biosciences, Inc shares in Q1 2023, an estimated $46.
- Citigroup first reported a position in Calithera Biosciences, Inc in Q4 2014 and held it in 29 quarters.
- Citigroup's Calithera Biosciences, Inc position peaked at $912K in Q3 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.